Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S. Topp, Jennifer L. Crombie, Susan O’Brien et al.|Blood|2024Cited by 28
Odronextamab Demonstrates Durable Complete Responses in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR-T Therapy: Outcomes from the ELM-1 StudyJennifer L. Crombie, Steve M Ansell, Matthew J. Matasar et al.|Blood|2023Cited by 8
Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 StudiesJohn N. Allan, Jon Arnason, Jennifer L. Crombie et al.|Blood|2024Cited by 6
Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 StudyMatthew J. Matasar, Jennifer L. Crombie, Max S. Topp et al.|Blood|2024Cited by 2